<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34132777</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>12</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1755-3245</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>118</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>06</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cardiovascular research</Title>
          <ISOAbbreviation>Cardiovasc Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The EP300/TP53 pathway, a suppressor of the Hippo and canonical WNT pathways, is activated in human hearts with arrhythmogenic cardiomyopathy in the absence of overt heart failure.</ArticleTitle>
        <Pagination>
          <StartPage>1466</StartPage>
          <EndPage>1478</EndPage>
          <MedlinePgn>1466-1478</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1093/cvr/cvab197</ELocationID>
        <Abstract>
          <AbstractText Label="AIMS">Arrhythmogenic cardiomyopathy (ACM) is a primary myocardial disease that typically manifests with cardiac arrhythmias, progressive heart failure, and sudden cardiac death (SCD). ACM is mainly caused by mutations in genes encoding desmosome proteins. Desmosomes are cell-cell adhesion structures and hubs for mechanosensing and mechanotransduction. The objective was to identify the dysregulated molecular and biological pathways in human ACM in the absence of overt heart failure.</AbstractText>
          <AbstractText Label="METHODS AND RESULTS">Transcriptomes in the right ventricular endomyocardial biopsy samples from three independent individuals carrying truncating mutations in the DSP gene and five control samples were analysed by RNA-Seq (discovery group). These cases presented with cardiac arrhythmias and had a normal right ventricular function. The RNA-Seq analysis identified ∼5000 differentially expressed genes (DEGs), which predicted suppression of the Hippo and canonical WNT pathways, among others. Dysregulated genes and pathways, identified by RNA-Seq, were tested for validation in the right and left ventricular tissues from five independent autopsy-confirmed ACM cases with defined mutations (validation group), who were victims of SCD and had no history of heart failure. Protein levels and nuclear localization of the cWNT and Hippo pathway transcriptional regulators were reduced in the right and left ventricular validation samples. In contrast, levels of acetyltransferase EP300, known to suppress the Hippo and canonical WNT pathways, were increased and its bona fide target TP53 was acetylated. RNA-Seq data identified apical junction, reflective of cell-cell attachment, as the most disrupted biological pathway, which were corroborated by disrupted desmosomes and intermediate filament structures. Moreover, the DEGs also predicted dysregulation of over a dozen canonical signal transduction pathways, including the Tec kinase and integrin signalling pathways. The changes were associated with increased apoptosis and fibro-adipogenesis in the ACM hearts.</AbstractText>
          <AbstractText Label="CONCLUSION">Altered apical junction structures are associated with activation of the EP300-TP53 and suppression of the Hippo/cWNT pathways in human ACM caused by defined mutations in the absence of an overt heart failure. The findings implicate altered mechanotransduction in the pathogenesis of ACM.</AbstractText>
          <CopyrightInformation>Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Rouhi</LastName>
            <ForeName>Leila</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Center for Cardiovascular Genetics, Institute of Molecular Medicine, University of Texas Health Sciences Center at Houston, 6770 Bertner Ave, Suite C900A, Houston, TX 77030, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fan</LastName>
            <ForeName>Siyang</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Center for Cardiovascular Genetics, Institute of Molecular Medicine, University of Texas Health Sciences Center at Houston, 6770 Bertner Ave, Suite C900A, Houston, TX 77030, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheedipudi</LastName>
            <ForeName>Sirisha M</ForeName>
            <Initials>SM</Initials>
            <Identifier Source="ORCID">0000-0002-3202-3229</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Center for Cardiovascular Genetics, Institute of Molecular Medicine, University of Texas Health Sciences Center at Houston, 6770 Bertner Ave, Suite C900A, Houston, TX 77030, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Braza-Boïls</LastName>
            <ForeName>Aitana</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Unidad de Cardiopatías Familiares, Muerte Súbita y Mecanismos de Enfermedad (CaFaMuSMe), Instituto de Investigación Sanitaria La Fe, Valencia, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Biomedical Network Research on Cardiovascular Diseases (CIBERCV), Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Molina</LastName>
            <ForeName>Maria Sabater</ForeName>
            <Initials>MS</Initials>
            <Identifier Source="ORCID">0000-0003-1352-1748</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Genetics and Microbiology, Cardiogenetic Laboratory, Instituto Murciano de Investigación Biosanitaria, Murcia, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yao</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-4003-4323</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, Fuwai Hospital, Peking Union Medical College, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Robertson</LastName>
            <ForeName>Matthew J</ForeName>
            <Initials>MJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cell Biology, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Coarfa</LastName>
            <ForeName>Cristian</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0002-4183-4939</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Cell Biology, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gimeno</LastName>
            <ForeName>Juan R</ForeName>
            <Initials>JR</Initials>
            <Identifier Source="ORCID">0000-0001-5818-1754</Identifier>
            <AffiliationInfo>
              <Affiliation>Center for Biomedical Network Research on Cardiovascular Diseases (CIBERCV), Madrid, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, Unidad CSUR Cardiopatias Familiares, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Molina</LastName>
            <ForeName>Pilar</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Unidad de Cardiopatías Familiares, Muerte Súbita y Mecanismos de Enfermedad (CaFaMuSMe), Instituto de Investigación Sanitaria La Fe, Valencia, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Servicio de Patologia, Instituto de Medicina Legal y Ciencias Forenses de Valencia, Histology Unit at the Universitat de València, Valencian, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gurha</LastName>
            <ForeName>Priyatansh</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Center for Cardiovascular Genetics, Institute of Molecular Medicine, University of Texas Health Sciences Center at Houston, 6770 Bertner Ave, Suite C900A, Houston, TX 77030, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zorio</LastName>
            <ForeName>Esther</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0003-3608-4210</Identifier>
            <AffiliationInfo>
              <Affiliation>Unidad de Cardiopatías Familiares, Muerte Súbita y Mecanismos de Enfermedad (CaFaMuSMe), Instituto de Investigación Sanitaria La Fe, Valencia, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Biomedical Network Research on Cardiovascular Diseases (CIBERCV), Madrid, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, Unidad de Cardiopatías Familiares, Servicio de Cardiología, Hospital Universitario y Politécnico La Fe, Valencia, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marian</LastName>
            <ForeName>Ali J</ForeName>
            <Initials>AJ</Initials>
            <Identifier Source="ORCID">0000-0002-1252-7120</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Center for Cardiovascular Genetics, Institute of Molecular Medicine, University of Texas Health Sciences Center at Houston, 6770 Bertner Ave, Suite C900A, Houston, TX 77030, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 HL151737</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R21 AG060413</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>S10 OD018135</GrantID>
            <Acronym>OD</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL132401</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cardiovasc Res</MedlineTA>
        <NlmUniqueID>0077427</NlmUniqueID>
        <ISSNLinking>0008-6363</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C495901">TP53 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.3.1.48</RegistryNumber>
          <NameOfSubstance UI="D050881">E1A-Associated p300 Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.3.1.48</RegistryNumber>
          <NameOfSubstance UI="C494360">EP300 protein, human</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001145" MajorTopicYN="N">Arrhythmias, Cardiac</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019571" MajorTopicYN="Y">Arrhythmogenic Right Ventricular Dysplasia</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009202" MajorTopicYN="Y">Cardiomyopathies</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016757" MajorTopicYN="N">Death, Sudden, Cardiac</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050881" MajorTopicYN="N">E1A-Associated p300 Protein</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D040542" MajorTopicYN="N">Mechanotransduction, Cellular</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016159" MajorTopicYN="N">Tumor Suppressor Protein p53</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060449" MajorTopicYN="N">Wnt Signaling Pathway</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Gene expression</Keyword>
        <Keyword MajorTopicYN="Y">Hippo pathway</Keyword>
        <Keyword MajorTopicYN="Y">RNA-sequencing</Keyword>
        <Keyword MajorTopicYN="Y">TP53</Keyword>
        <Keyword MajorTopicYN="Y">WNT pathway</Keyword>
        <Keyword MajorTopicYN="Y"> Cardiomyopathy</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2022</Year>
          <Month>6</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>16</Day>
          <Hour>12</Hour>
          <Minute>23</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34132777</ArticleId>
        <ArticleId IdType="pmc">PMC9074970</ArticleId>
        <ArticleId IdType="doi">10.1093/cvr/cvab197</ArticleId>
        <ArticleId IdType="pii">6300515</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Corrado D, Link MS, Calkins H.  Arrhythmogenic right ventricular cardiomyopathy. N Engl J Med  2017;376:61–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28052233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gandjbakhch E, Redheuil A, Pousset F, Charron P, Frank R.  Clinical diagnosis, imaging, and genetics of arrhythmogenic right ventricular cardiomyopathy/dysplasia: JACC State-of-the-Art Review. J Am Coll Cardiol  2018;72:784–804.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30092956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Groeneweg JA, Bhonsale A, James CA, Te Riele AS, Dooijes D, Tichnell C, Murray B, Wiesfeld AC, Sawant AC, Kassamali B, Atsma DE, Volders PG, de Groot NM, de Boer K, Zimmerman SL, Kamel IR, van der Heijden JF, Russell SD, Jan Cramer M, Tedford RJ, Doevendans PA, van Veen TA, Tandri H, Wilde AA, Judge DP, van Tintelen JP, Hauer RN, Calkins H.  Clinical presentation, long-term follow-up, and outcomes of 1001 arrhythmogenic right ventricular dysplasia/cardiomyopathy patients and family members. Circ Cardiovasc Genet  2015;8:437–446.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25820315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Thiene G.  The research venture in arrhythmogenic right ventricular cardiomyopathy: a paradigm of translational medicine. Eur Heart J  2015;36:837–846.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25636746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Corrado D, Basso C, Schiavon M, Thiene G.  Screening for hypertrophic cardiomyopathy in young athletes. N Engl J Med  1998;339:364–369.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9691102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mast TP, Teske AJ, Vd Heijden JF, Groeneweg JA, Te Riele AS, Velthuis BK, Hauer RN, Doevendans PA, Cramer MJ.  Left ventricular involvement in arrhythmogenic right ventricular dysplasia/cardiomyopathy assessed by echocardiography predicts adverse clinical outcome. J Am Soc Echocardiogr  2015;28:1103–1113.e1109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26025724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Corrado D, Basso C, Judge DP.  Arrhythmogenic cardiomyopathy. Circ Res  2017;121:784–802.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28912183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
van Tintelen JP, Entius MM, Bhuiyan ZA, Jongbloed R, Wiesfeld AC, Wilde AA, van der Smagt J, Boven LG, Mannens MM, van Langen IM, Hofstra RM, Otterspoor LC, Doevendans PA, Rodriguez LM, van Gelder IC, Hauer RN.  Plakophilin-2 mutations are the major determinant of familial arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation  2006;113:1650–1658.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16567567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Castelletti S, Vischer AS, Syrris P, Crotti L, Spazzolini C, Ghidoni A, Parati G, Jenkins S, Kotta MC, McKenna WJ, Schwartz PJ, Pantazis A.  Desmoplakin missense and non-missense mutations in arrhythmogenic right ventricular cardiomyopathy: genotype-phenotype correlation. Int J Cardiol  2017;249:268–273.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28527814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Broussard JA, Getsios S, Green KJ.  Desmosome regulation and signaling in disease. Cell Tissue Res  2015;360:501–512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4489137</ArticleId>
            <ArticleId IdType="pubmed">25693896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nitoiu D, Etheridge SL, Kelsell DP.  Insights into desmosome biology from inherited human skin disease and cardiocutaneous syndromes. Cell Commun Adhes  2014;21:129–140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24738885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Garcia-Gras E, Lombardi R, Giocondo MJ, Willerson JT, Schneider MD, Khoury DS, Marian AJ.  Suppression of canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. J Clin Invest  2006;116:2012–2021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1483165</ArticleId>
            <ArticleId IdType="pubmed">16823493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chen SN, Gurha P, Lombardi R, Ruggiero A, Willerson JT, Marian AJ.  The hippo pathway is activated and is a causal mechanism for adipogenesis in arrhythmogenic cardiomyopathy. Circ Res  2014;114:454–468.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3946717</ArticleId>
            <ArticleId IdType="pubmed">24276085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Molina P, Sanz-Sanchez J, Fenollosa M, Martinez-Matilla M, Giner J, Zorio E.  Arrhythmogenic cardiomyopathy with left ventricular involvement versus ischemic heart disease: lessons learned from the family study and the reviewed autopsy of a young male. Forensic Sci Res  2019;4:274–279.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6713184</ArticleId>
            <ArticleId IdType="pubmed">31489393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cheedipudi SM, Hu J, Fan S, Yuan P, Karmouch J, Czernuszewicz G, Robertson MJ, Coarfa C, Hong K, Yao Y, Campbell H, Wehrens X, Gurha P, Marian AJ.  Exercise restores dysregulated gene expression in a mouse model of arrhythmogenic cardiomyopathy. Cardiovasc Res  2020;116:1199–1213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7177479</ArticleId>
            <ArticleId IdType="pubmed">31350552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Auguste G, Rouhi L, Matkovich SJ, Coarfa C, Robertson MJ, Czernuszewicz G, Gurha P, Marian AJ.  BET bromodomain inhibition attenuates cardiac phenotype in myocyte-specific Lamin A/C-deficient mice. J Clin Invest  2020;130:4740–4758.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7456228</ArticleId>
            <ArticleId IdType="pubmed">32484798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chen SN, Lombardi R, Karmouch J, Tsai JY, Czernuszewicz G, Taylor MRG, Mestroni L, Coarfa C, Gurha P, Marian AJ.  DNA damage response/TP53 pathway is activated and contributes to the pathogenesis of dilated cardiomyopathy associated with LMNA (Lamin A/C) mutations. Circ Res  2019;124:856–873.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6460911</ArticleId>
            <ArticleId IdType="pubmed">30696354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Auguste G, Gurha P, Lombardi R, Coarfa C, Willerson JT, Marian AJ.  Suppression of activated FOXO transcription factors in the heart prolongs survival in a mouse model of laminopathies. Circ Res  2018;122:678–692.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5834384</ArticleId>
            <ArticleId IdType="pubmed">29317431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kim D, Paggi JM, Park C, Bennett C, Salzberg SL.  Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol  2019;37:907–915.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7605509</ArticleId>
            <ArticleId IdType="pubmed">31375807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Risso D, Ngai J, Speed TP, Dudoit S.  Normalization of RNA-seq data using factor analysis of control genes or samples. Nat Biotechnol  2014;32:896–902.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4404308</ArticleId>
            <ArticleId IdType="pubmed">25150836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Love MI, Huber W, Anders S.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol  2014;15:550.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4302049</ArticleId>
            <ArticleId IdType="pubmed">25516281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rouhi L, Cheedipudi SM, Chen SN, Fan S, Lombardi R, Chen X, Coarfa C, Robertson MJ, Gurha P, Marian AJ.  Haplo-insufficiency of Tmem43 in cardiac myocytes activates the DNA damage response pathway leading to a late-onset senescence-associated pro-fibrotic cardiomyopathy. Cardiovasc Res  2020;doi: 10.1093/cvr/cvaa300.</Citation>
        </Reference>
        <Reference>
          <Citation>
Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, Calkins H, Corrado D, Cox MG, Daubert JP, Fontaine G, Gear K, Hauer R, Nava A, Picard MH, Protonotarios N, Saffitz JE, Sanborn DM, Steinberg JS, Tandri H, Thiene G, Towbin JA, Tsatsopoulou A, Wichter T, Zareba W.  Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Eur Heart J  2010;31:806–814.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2848326</ArticleId>
            <ArticleId IdType="pubmed">20172912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
López-Ayala JM, Gómez-Milanés I, Sánchez Muñoz JJ, Ruiz-Espejo F, Ortíz M, González-Carrillo J, López-Cuenca D, Oliva-Sandoval MJ, Monserrat L, Valdés M, Gimeno JR.  Desmoplakin truncations and arrhythmogenic left ventricular cardiomyopathy: characterizing a phenotype. Europace  2014;16:1838–1846.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24938629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ma Z, Huebsch N, Koo S, Mandegar MA, Siemons B, Boggess S, Conklin BR, Grigoropoulos CP, Healy KE.  Contractile deficits in engineered cardiac microtissues as a result of MYBPC3 deficiency and mechanical overload. Nat Biomed Eng  2018;2:955–967.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6482859</ArticleId>
            <ArticleId IdType="pubmed">31015724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li J, Sutter C, Parker DS, Blauwkamp T, Fang M, Cadigan KM.  CBP/p300 are bimodal regulators of Wnt signaling. EMBO J  2007;26:2284–2294.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1864967</ArticleId>
            <ArticleId IdType="pubmed">17410209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Miyajima C, Kawarada Y, Inoue Y, Suzuki C, Mitamura K, Morishita D, Ohoka N, Imamura T, Hayashi H.  Transcriptional coactivator TAZ negatively regulates tumor suppressor p53 activity and cellular senescence. Cells  2020;9:171.</Citation>
        </Reference>
        <Reference>
          <Citation>
Puzzi L, Borin D, Gurha P, Lombardi R, Martinelli V, Weiss M, Andolfi L, Lazzarino M, Mestroni L, Marian AJ, Sbaizero O.  Knock down of plakophillin 2 dysregulates adhesion pathway through upregulation of miR200b and alters the mechanical properties in cardiac cells. Cells  2019;8:1639.</Citation>
        </Reference>
        <Reference>
          <Citation>
Nelson WJ, Nusse R.  Convergence of Wnt, beta-catenin, and cadherin pathways. Science  2004;303:1483–1487.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3372896</ArticleId>
            <ArticleId IdType="pubmed">15001769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Heallen T, Zhang M, Wang J, Bonilla-Claudio M, Klysik E, Johnson RL, Martin JF.  Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science  2011;332:458–461.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3133743</ArticleId>
            <ArticleId IdType="pubmed">21512031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Varelas X, Miller BW, Sopko R, Song S, Gregorieff A, Fellouse FA, Sakuma R, Pawson T, Hunziker W, McNeill H, Wrana JL, Attisano L.  The Hippo pathway regulates Wnt/beta-catenin signaling. Dev Cell  2010;18:579–591.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20412773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Xu F, Wang YL, Chang JJ, Du SC, Diao L, Jiang N, Wang HJ, Ma D, Zhang J.  Mammalian sterile 20-like kinase 1/2 inhibits the Wnt/beta-catenin signalling pathway by directly binding casein kinase 1epsilon. Biochem J  2014;458:159–169.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24180524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li Q, Sun Y, Jarugumilli GK, Liu S, Dang K, Cotton JL, Xiol J, Chan PY, DeRan M, Ma L, Li R, Zhu LJ, Li JH, Leiter AB, Ip YT, Camargo FD, Luo X, Johnson RL, Wu X, Mao J.  Lats1/2 sustain intestinal stem cells and Wnt activation through TEAD-dependent and independent transcription. Cell Stem Cell  2020;26:675–692.e678.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7310193</ArticleId>
            <ArticleId IdType="pubmed">32259481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Imajo M, Miyatake K, Iimura A, Miyamoto A, Nishida E.  A molecular mechanism that links Hippo signalling to the inhibition of Wnt/beta-catenin signalling. EMBO J  2012;31:1109–1122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3297994</ArticleId>
            <ArticleId IdType="pubmed">22234184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Park HW, Kim YC, Yu B, Moroishi T, Mo JS, Plouffe SW, Meng Z, Lin KC, Yu FX, Alexander CM, Wang CY, Guan KL.  Alternative Wnt signaling activates YAP/TAZ. Cell  2015;162:780–794.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4538707</ArticleId>
            <ArticleId IdType="pubmed">26276632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bhonsale A, Groeneweg JA, James CA, Dooijes D, Tichnell C, Jongbloed JD, Murray B, Te Riele AS, van den Berg MP, Bikker H, Atsma DE, de Groot NM, Houweling AC, van der Heijden JF, Russell SD, Doevendans PA, van Veen TA, Tandri H, Wilde AA, Judge DP, van Tintelen JP, Calkins H, Hauer RN.  Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. Eur Heart J  2015;36:847–855.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25616645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Augusto JB, Eiros R, Nakou E, Moura-Ferreira S, Treibel TA, Captur G, Akhtar MM, Protonotarios A, Gossios TD, Savvatis K, Syrris P, Mohiddin S, Moon JC, Elliott PM, Lopes LR.  Dilated cardiomyopathy and arrhythmogenic left ventricular cardiomyopathy: a comprehensive genotype-imaging phenotype study. Eur Heart J Cardiovasc Imaging  2020;21:326–336.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31317183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Smith ED, Lakdawala NK, Papoutsidakis N, Aubert G, Mazzanti A, McCanta AC, Agarwal PP, Arscott P, Dellefave-Castillo LM, Vorovich EE, Nutakki K, Wilsbacher LD, Priori SG, Jacoby DL, McNally EM, Helms AS.  Desmoplakin cardiomyopathy, a fibrotic and inflammatory form of cardiomyopathy distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathy. Circulation  2020;141:1872–1884.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7286080</ArticleId>
            <ArticleId IdType="pubmed">32372669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cipriani A, Bauce BD, Lazzari M, Rigato I, Bariani R, Meneghin S, Pilichou K, Motta R, Aliberti C, Thiene G, McKenna WJ, Zorzi A, Iliceto S, Basso CP, Marra M, Corrado D.  Arrhythmogenic right ventricular cardiomyopathy: characterization of left ventricular phenotype and differential diagnosis with dilated cardiomyopathy. J Am Heart Assoc  2020;9:e014628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7335583</ArticleId>
            <ArticleId IdType="pubmed">32114891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Haas J, Frese KS, Peil B, Kloos W, Keller A, Nietsch R, Feng Z, Müller S, Kayvanpour E, Vogel B, Sedaghat-Hamedani F, Lim W-K, Zhao X, Fradkin D, Köhler D, Fischer S, Franke J, Marquart S, Barb I, Li DT, Amr A, Ehlermann P, Mereles D, Weis T, Hassel S, Kremer A, King V, Wirsz E, Isnard R, Komajda M, Serio A, Grasso M, Syrris P, Wicks E, Plagnol V, Lopes L, Gadgaard T, Eiskjær H, Jørgensen M, Garcia-Giustiniani D, Ortiz-Genga M, Crespo-Leiro MG, Deprez RHLD, Christiaans I, van Rijsingen IA, Wilde AA, Waldenstrom A, Bolognesi M, Bellazzi R, Mörner S, Bermejo JL, Monserrat L, Villard E, Mogensen J, Pinto YM, Charron P, Elliott P, Arbustini E, Katus HA, Meder B.  Atlas of the clinical genetics of human dilated cardiomyopathy. Eur Heart J  2015;36:1123–1135a.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25163546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dubash AD, Kam CY, Aguado BA, Patel DM, Delmar M, Shea LD, Green KJ.  Plakophilin-2 loss promotes TGF-beta1/p38 MAPK-dependent fibrotic gene expression in cardiomyocytes. J Cell Biol  2016;212:425–438.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4754716</ArticleId>
            <ArticleId IdType="pubmed">26858265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Shoykhet M, Trenz S, Kempf E, Williams T, Gerull B, Schinner C, Yeruva S, Waschke J.  Cardiomyocyte adhesion and hyperadhesion differentially require ERK1/2 and plakoglobin. JCI Insight  2020;5:</Citation>
        </Reference>
        <Reference>
          <Citation>
Hall CL, Gurha P, Sabater-Molina M, Asimaki A, Futema M, Lovering RC, Suarez MP, Aguilera B, Molina P, Zorio E, Coarfa C, Robertson MJ, Cheedipudi SM, Ng KE, Delaney P, Hernandez JP, Pastor F, Gimeno JR, McKenna WJ, Marian AJ, Syrris P.  RNA sequencing-based transcriptome profiling of cardiac tissue implicates novel putative disease mechanisms in FLNC-associated arrhythmogenic cardiomyopathy. Int J Cardiol  2020;302:124–130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6940594</ArticleId>
            <ArticleId IdType="pubmed">31843279</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
